Epicore BioNetworks Inc. Announces New Board Director and Stock Option Exercise
CALGARY, Alberta, Jan. 19, 2013 /PRNewswire/ -- The Board of Directors of Epicore BioNetworks Inc. is pleased to announce a new director has joined the board, effective January 16, 2013. The Board welcomes Mr. Alan Savage of Vancouver, British Columbia, Canada.
Mr. Savage is founder and president of Southern Gold Resources Ltd. of Vancouver. Alan brings to the Company experience and expertise obtained over a long and successful career in capital markets, much of it through the investment business of Southern Gold Resources Ltd, owner of 4,052,000 shares of Epicore.
Epicore announces that one of its Board directors, Fred N. Boulos, exercised 50,000 of his allotted common stock options. The options were exercised at the price granted, which was Cdn. $0.145 per share. With this transaction Epicore common shares outstanding increased 0.2% to 24,557,179. Mr. Boulos's ownership of Epicore shares increased to 464,000, which is 1.9% of shares outstanding.
Epicore BioNetworks Inc. is a leading producer of environmental biotechnology and animal nutrition products. It manufactures in the USA and markets worldwide to a variety of industries to reduce environmental pollution and increase operational productivity.
Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). [Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.]
For further information:
Mr. William P. Long (Chief Executive Officer)
SOURCE Epicore BioNetworks Inc.
Skapa innehåll för din webbplats
Förbättra din webbplats eller blogg med PR Newswires skräddarsydda nyhetsflöden.
Kontakta PR Newswire
Skicka oss ett mail till firstname.lastname@example.org eller ring oss på +46 (0)8 1200 1300
Bli en PR Newswire kund
Begär mer information , se PR Newswire produkter & tjänster eller ring oss på +46 (0)8 1200 1300